Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
| Status: | Archived |
|---|---|
| Conditions: | Breast Cancer, Colorectal Cancer, Ovarian Cancer, Cervical Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2008 |
A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly
specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists
of a dose escalation part followed by a MTD expansion part.
Once the MTD has been defined, the MTD expansion part will be opened for enrollment.
We found this trial at
2
sites
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials